Back to Search
Start Over
Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer.
- Source :
- Oncology & Therapy; Dec2023, Vol. 11 Issue 4, p481-493, 13p
- Publication Year :
- 2023
-
Abstract
- Introduction: Many patients with human epidermal growth factor receptor-2-positive metastatic breast cancer (HER2+ mBC) require subsequent lines of therapy (LOTs) after being treated with pertuzumab and trastuzumab-based regimens in the first line (1L). Although the efficacy of the second-line (2L) therapies has been demonstrated in clinical trials, the real-world effectiveness of these treatments is understudied. This retrospective cohort study assessed the real-world treatment patterns and outcomes for patients with HER2+ mBC following 1L therapy with pertuzumab and trastuzumab-based regimens in the United States (US) during 2015–2019. Methods: Adults with HER2+ mBC in the US who initiated 1L pertuzumab and trastuzumab-based regimens between 01/01/2015 and 09/30/2019 and had ≥ 60 days of follow-up after 1L initiation were identified from the IQVIA Oncology Electronic Medical Records database. The regimens utilized in 2L following 1L pertuzumab and trastuzumab-based regimens were described. Median treatment duration and time to treatment failure were reported for 2L based on Kaplan–Meier analyses. Results: Of the 710 eligible patients who received pertuzumab and trastuzumab-based regimens in 1L (median age: 57.0 years [interquartile range: 48.0–65.0]; median follow-up: 20.3 months; median 1L duration: 15.3 months), 222 (31.3%) initiated 2L. The most common regimens in 2L were ado-trastuzumab emtansine (T-DM1)-based regimens (n = 159 [71.6%]), followed by lapatinib-based (n = 21 [9.5%]) and neratinib-based (n = 18 [8.1%]) regimens. The median treatment duration and time to treatment failure were 5.9 (95% CI: 5.0, 8.7) and 8.6 (7.3, 11.5) months, respectively, among patients initiating 2L, and 5.7 (4.7, 7.8) and 7.9 (6.5, 10.0) months among those receiving 2L T-DM1. Conclusions: Most patients with HER2+ mBC requiring additional treatments after 1L pertuzumab and trastuzumab-based regimens utilized T-DM1 in 2L during 2015–2019. The short median treatment duration and time to treatment failure highlight an unmet need that can potentially be fulfilled by recently approved treatment options. [ABSTRACT FROM AUTHOR]
- Subjects :
- THERAPEUTIC use of monoclonal antibodies
THERAPEUTIC use of antineoplastic agents
HORMONE therapy
TRASTUZUMAB
TREATMENT duration
METASTASIS
RETROSPECTIVE studies
ACQUISITION of data
TREATMENT effectiveness
CANCER patients
RESEARCH funding
KAPLAN-Meier estimator
MEDICAL records
DESCRIPTIVE statistics
DEMOGRAPHY
TUMOR markers
BREAST tumors
LONGITUDINAL method
Subjects
Details
- Language :
- English
- ISSN :
- 23661070
- Volume :
- 11
- Issue :
- 4
- Database :
- Complementary Index
- Journal :
- Oncology & Therapy
- Publication Type :
- Academic Journal
- Accession number :
- 173822086
- Full Text :
- https://doi.org/10.1007/s40487-023-00241-8